Vancouver, B.C. April 16, 2009 – biOasis Technologies Inc. (BTI.V) is pleased to announce that it has entered into a private placement of up to 1,000,000 units at a purchase price of $0.50 per unit for gross proceeds of up to $500,000. Each unit will consist of one common share and one share purchase warrant entitling the investor to purchase an additional common share at a price of $0.60 per share for a period of one year. Bolder Investment Partners, Ltd. will be paid a 10% Finder’s Fee in connection with the financing.

ABOUT BIOASIS:

biOasis Technologies Inc. is a Canadian Biotechnology company engaged in the development and commercialization of diagnostics and therapeutics related to neurological diseases. t has extensive and comprehensive intellectual property (“IP”) which it obtained from the University of British Columbia. The Company’s initial area of focus will be on the utilization of the IP to pursue a biomarker for the diagnosis of Alzheimer’s disease. The IP has been corroborated in double blinded and successive multi-site clinical trials.

According to the Centers for Disease Control and Prevention (“CDC”), Alzheimer’s disease was listed as the “underlying cause of death” for 65,829 Americans in 2004. It was the seventh leading cause of death for people of all ages and the fifth leading cause of death in people age 65 and older.

To find out more about biOasis Technologies Inc. visit www.bioasis.ca.

On Behalf of the Board of Directors

Robin Hutchison
Director and CEO
(604) 542-5059
rob@bioasis.ca

“The TSX Venture Exchange has neither approved nor disapproved the contents of this press release.”